Novel Treatments and New Research in Hodgkin Lymphoma

In this video Cancer Network interviews Dr. Joseph Connors, clinical director at the Centre for Lymphoid Cancer, BC Cancer Agency, and Clinical Professor, University of British Columbia, Vancouver.

Dr. Connors gives an overview of the results presented here at ASCO of the phase II trial of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma, and discusses the most intriguing work currently being done with novel agents used to treat relapsed or refractory Hodgkin lymphoma.